ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer [Yahoo! Finance]
Cerus Corporation (CERS)
Last cerus corporation earnings: 2/20 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cerus.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the cGAS-STING pathway to address indications in inflammation, autoimmunity and oncology, announced the appointment of Thomas W. Dubensky, Jr., Ph.D., as president and chief executive officer and a member of the Board of Directors, effective immediately. Dr. Dubensky is a veteran biopharma executive and entrepreneur with a track record of strategic leadership in both private and public companies. He brings significant expertise in the discovery, development and translation of novel small molecule-, biologic- and vector-based therapies, having led teams advancing several first-in-human drug candidates. Most recently, Dr. Dubensky was the founding CEO of Tempest Therapeutics, joining the company in 2017. Earlier in his career, he held roles leading discovery biology, development and clinical
Show less
Read more
Impact Snapshot
Event Time:
CERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERS alerts
High impacting Cerus Corporation news events
Weekly update
A roundup of the hottest topics
CERS
News
- Cerus Co. (NASDAQ: CERS) had its price target raised by analysts at Cantor Fitzgerald from $3.00 to $4.00. They now have an "overweight" rating on the stock.MarketBeat
- Cerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Cerus Corporation Announces First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Cerus GAAP EPS of -$0.05 in-line, revenue of $43.4M beats by $5.05M [Seeking Alpha]Seeking Alpha
- Cerus Corporation Announces First Quarter 2024 Financial ResultsBusiness Wire
CERS
Earnings
- 5/2/24 - Miss
CERS
Sec Filings
- 5/14/24 - Form 4
- 5/13/24 - Form 4
- 5/10/24 - Form 4
- CERS's page on the SEC website